Zang Yun-Xiao, Peng Rong-Mei, Ben Han-Zhi, Qu Jing-Hao, Xiao Ge-Ge, Shuai Li-Xue, Zhang Pei, Feng Li-Na, Hong Jing
Department of Ophthalmology, Peking University Third Hospital, Beijing 100191, China.
Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing 100191, China.
Int J Ophthalmol. 2023 Jan 18;16(1):53-59. doi: 10.18240/ijo.2023.01.08. eCollection 2023.
To investigate corneal graft survival rate and endothelial cell density (ECD) loss after keratoplasty in cytomegalovirus (CMV) positive patients.
This was a retrospective cohort study. We analyzed the clinical data of patients who underwent viral DNA detection in aqueous humor/corneal tissue collected during keratoplasty from March 2015 to December 2018 at the Peking University Third Hospital, Beijing, China. To further evaluate the effect of CMV on graft survival rate and ECD loss, patients were divided into three groups: 1) CMV DNA positive (CMV+) group; 2) viral DNA negative (virus-) group, comprising virus- group eyes pairwise matched to eyes in the CMV+ group according to ocular comorbidities; 3) control group, comprising virus- group eyes without ocular comorbidities. The follow-up indicators including graft survival rate, ECD, ECD loss, and central corneal thickness (CCT), were analyzed by Tukey honestly significant difference (HSD) test.
Each group included 29 cases. The graft survival rate in CMV+ group were lowest among the three groups (=0.000). No significant difference in donor graft ECD was found among three groups (=0.54). ECD in the CMV+ group was lower than the virus- group at 12 (=0.009), and 24mo (=0.002) after keratoplasties. Furthermore, ECD loss was higher in the CMV+ group than in the virus- group in the middle stage (6-12mo) post-keratoplasty (=0.017), and significantly higher in the early stage (0-6mo) in the virus- group than in the control group (=0.000).
CMV reduces the graft survival rate and exerts persistent detrimental effects on the ECD after keratoplasty. The graft ECD loss associate with CMV infection mainly occurrs in the middle stage (6-12mo postoperatively), while ocular comorbidities mainly affects ECD in the early stage (0-6mo postoperatively).
研究巨细胞病毒(CMV)阳性患者角膜移植术后的角膜植片存活率及内皮细胞密度(ECD)损失情况。
这是一项回顾性队列研究。我们分析了2015年3月至2018年12月在中国北京北京大学第三医院接受角膜移植术时采集的房水/角膜组织中病毒DNA检测的患者的临床资料。为进一步评估CMV对植片存活率和ECD损失的影响,患者被分为三组:1)CMV DNA阳性(CMV+)组;2)病毒DNA阴性(virus-)组,根据眼部合并症与CMV+组的眼睛进行配对匹配;3)对照组,由无眼部合并症的virus-组眼睛组成。通过Tukey真实显著差异(HSD)检验分析随访指标,包括植片存活率、ECD、ECD损失和中央角膜厚度(CCT)。
每组包括29例。CMV+组的植片存活率在三组中最低(=0.000)。三组之间供体植片ECD无显著差异(=0.54)。角膜移植术后12个月(=0.009)和24个月(=0.002)时,CMV+组的ECD低于virus-组。此外,角膜移植术后中期(6 - 12个月)CMV+组的ECD损失高于virus-组(=0.017),virus-组早期(0 - 6个月)的ECD损失显著高于对照组(=0.000)。
CMV降低角膜移植术后的植片存活率,并对ECD产生持续的有害影响。与CMV感染相关的植片ECD损失主要发生在中期(术后6 - 12个月),而眼部合并症主要影响早期(术后0 - 6个月)的ECD。